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During  the  past  several  years,  data  has  been  steadily  increasing  which 
establishes a  relationship  between mammalian  RNA tumor virus constituents 
and similar molecules in human tumors. Thus far most of the evidence is based 
on DNA-RNA  hybridization  studies  and  reverse transcriptase  activity  (1),  al- 
though  there  have  been  reports  establishing  some  serological  relationships 
between antigens in human  cancers, particularly human  leukemias,  and those 
of RNA tumor viruses or their transformed cells (2-4). 
Most  of what  is  known  about  mammalian  oncogenic  RNA  virus  antigens 
comes  from  studies  with  the  major  internal  protein  (p30) ~ and  the  primary 
surface  glycoprotein  (gp71)  of the  viruses  (5).  These  molecules  from  all  well 
studied mammalian viruses including those of primates, contain multiple anti- 
genic determinants (6). Both p30 and gp71 molecules are found at the surface of 
cells  which  harbor  the  virus  genome  (7,  8).  The  expression  of some  of  the 
determinants  of these  molecules on the  cell surface can be noncoordinate  and 
independent  of virus elaboration or cell transformation (8, 9) and appears to be 
subjected  to genetic control by the  host (10-12).  Antisera  to purified gp71  and 
p30 are  cytotoxic for some animal cells which  express these  antigens  on their 
surface (8). 
The serological specificity of human leukemia-associated antigens detected by 
certain  cytotoxic  nonhuman  primate  antisera  to  human  leukemia  cells  have 
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been previously described  (13,  14)  and will  not be  detailed  here.  However,  in 
order  to  clarify  the  serological  data  in  this  report,  a  brief  summary  of the 
specificity  of these  reagents  follows.  Primate  antisera  to  cells  from  chronic 
lymphocytic  leukemia  (CLL)  patients  detect  membrane  antigens  which  are 
specific for cells from CLL patients and which cross-react with cells from acute 
lymphoblastic  leukemia  (ALL).  These  antisera  do  not  react  with  cells  from 
myeloid leukemia patients.  In contrast, primate antisera to cells from myeloid 
leukemia patients can be shown to detect antigens on cells of some patients with 
myeloid leukemia  which are not present on cells of patients with ALL or CLL. 
There are several myeloid leukemia-associated antigens detected by the various 
nonhuman  primate  antisera.  Moreover,  not  all  of  the  patients  with  acute 
myelocytic leukemia (AML) and chronic granulocytic (myeloid) leukemia (CGL) 
have cells  which  react with each  of the  simian  antisera  to myeloid  leukemia 
cells.  Absorption  studies  of the  antisera  with  individual  AML  and  CGL  cell 
donors indicate that these antisera can detect antigens which are cross-reactive 
between AML and CGL cells and may also detect antigens which are unique for 
cells of certain  AML and CGL donors (14). 
The  studies described below utilized,  in addition to the primate  antisera  to 
human leukemia-associated  antigens,  a variety of well studied oncogenic RNA 
virus  structural  components  and  their  corresponding  antisera.  The  data  re- 
ported establishes a complex antigenic relationship between certain membrane- 
associated  antigens of human myeloid leukemia cells and the virion molecules 
gp71 and p30 from Friend murine leukemia virus (FLV). 
Materials and Methods 
Viruses.  FLV was grown in a  continuous cell culture line (Eveline) originally obtained by 
infection of Sch~ifer Tfibingen mouse strain (STU) embryos with FLV (15). Animal passaged FLV 
was kindly provided by Dr. C. Friend, Mt. Sinai School of Medicine, New York and passed in our 
laboratory in DBA/2J mice. Rauscher murine leukemia virus  (RLV) and Gross (GLV) murine 
leukemia virus  were a gift  from R. Gilden, Flow Laboratories,  Inc.,  Bethesda, Md. The Rickard 
strain  of  feline  leukemia  virus  (FeLV) was a gift  from F. de Noronha, Cornell  University Medical 
College,  New York. Avian  myeloblastosis  virus  (AMV) was  harvested from  the  plasma  of  leukemic 
chickens.  Murine mammary tumor  virus  (MMTV) purified  from RIII  mouse milk  was provided by 
W. Parks, NCI, Bethesda,  Md.  All virus  preparations were purified extensively by density 
gradient  centrifugation. 
Isolation of  Viral Structural Polypeptides.  The isolation  of  the  p30  polypeptide  (30,000  tool  wt) 
and other polypeptides of FLV  and FeLV has been described (16).  The major FLV  surface 
glycoprotein  of  71,000  mol wt (gp71)  was also  obtained from virus  grown in  Eveline cells  and was 
prepared as described  by Moennig et al. (17).  AMV  polypeptides  were isolated  in an analogous 
manner (18).  AMV  gp85 (glycoprotein  of 85,000 mol wt) was purified  from disrupted AMV  as 
recently  described  (19).  For complete nomenclature of  these components see August et al. (6). 
The major  MMTV  glycoprotein  (gp52)  was  isolated  from  MMTV  with  0.3%  deoxycholate (DOC), 
0.1 M  NaCl, and 0.01 M  Tris,  pH 8. Sodium dodecyl sulfate  (SDS) gel electrophoresis  of this 
preparation indicated  six  components in major amounts having tool  wt of  10,000,  12,000,  14,000, 
27,000,  36,000,  52,000,  and 65,000  daltons.  Minor amounts of  proteins  were observed above 65,000 
daltons  and at  42,000  and 48,000  daltons.  After  dialysis  to  remove DOC, this  material was  reacted 
with concanavalin A covalently  linked to agarose and washed with diluted  salt  solution.  Subse- 
quent  elution  with  methyl  mannoside  gave  a preparation  containing  gp36  and  gp52.  This  material, 
when passed through  Sephadex G75, yielded  gp52 and  gp36  as  separable  entities.  Antisera to  gp52 
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Solubilization of  Leukemia Antigens with Sodium DOC.  Leukemic cells from spleen or periph- 
eral blood were washed three times with saline at 800g and stored at -70°C.  The cell pellets (40- 
200 ml) were homogenized in a VirTis apparatus (Model 45; VirTis Co., Inc., Gardiner, N. Y.) for 10 
min at 4°C in the presence of 100/~g/ml DNase (Sigma Chemical Co., St. Louis, Mo.). The material 
was diluted fivefold with 0.02  M  Tris.HC1,  0.2 M  NaCl,  pH 8.5,  and DOC  was added to a  final 
concentration of 0.5%.  This suspension was then placed  in a  Branson sonifier (Bransonic 220; 
Branson Instruments Co., Stanford, Conn.) for 10 min at 37°C and centrifuged at 40,000 g  for 120 
min in a  Beckman  L3-50  ultracentrifuge  (Beckman  Instruments,  Inc.,  Fullerton,  Calif.).  The 
supernate containing the antigenic activity was dialyzed against distilled water,  concentrated, 
and resolubilized in 0.1% Triton X-100, The material was then partially purified by gel filtration 
on Sephadex G200 in the presence of 0.05% DOC in 0.02 M Tris.HCl, and 0.2 M NaC1, pH 8.0. 
Antiserum to Human Leukemia Antigens.  The nonhuman primate antisera to human leuke- 
mia cell antigens used  in this study have been listed and the specificity described  in detail in 
earlier reports (13,  14). These sera include a chimpanzee (Pan-troglodytes) antiserum to cells from 
a  CLL  donor (C1),  a  chimpanzee antiserum to cells from an AML patient (C2)  and  a  monkey 
(Macaca-speciosa) antiserum to cells from a CGL donor (M3). These antisera were heat inactivated 
at 56°C  and  then absorbed with human erythrocytes (HRBC)  and peripheral  blood leukocytes 
(HWBC) from normal donors until they failed to react with lymphocytes from a  panel of HL-A- 
typed  normal donors.  Such absorbed antisera did  not react  with cells from any of the  normal 
donors tested but were cytotoxic to cells from leukemia patients. 
Antisera to  Viruses.  Information on  the  antisera  to  RNA  tumor  viruses or  their purified 
antigens which were used in this report are described in Table I. 
Absorption  of  Antisera to Oncornaviruses.  The rabbit or goat antisera to the RNA tumor virus 
antigens were heat inactivated at 56°C for 30 min and subsequently absorbed with HRBC from 
blood group A  and B donors until they no longer agglutinated these cells.  Such HRBC-absorbed 
antisera did not react  with lymphocytes prepared from peripheral  blood of normal volunteers. 
Portions of the antisera absorbed with normal HRBC were then absorbed with either HWBC from 
normal adult donors,  mouse spleen cells,  mouse embryo cells,  or cells from individual leukemic 
patients at a  concentration of 2  ×  l0  s cells/ml of serum.  Other samples of the HRBC-absorbed 
antisera  were  absorbed  with either human  platelets devoid of other peripheral  blood  cells  or 
peripheral blood lymphocytes or neutrophils. For the preparation of platelets, blood collected in 
EDTA was centrifuged at 800 g  and the supernate recentrifuged at 1,000 g  for 10 rain to remove 
erythrocytes and leukocytes.  The platelet-rich supernate was then centrifuged at 4,000 g  for 20 
rain at 4°C.  The platelets were thrice washed in isotonic saline before being used for absorption. 
Purified lymphocytes and neutrophils were prepared from heparinized peripheral blood of normal 
donors by gradient centrifugation. Erythrocytes were sedimented with 5% dextran in the presence 
of carbonyl iron and the leukocyte-rich supernate was centrifuged over a Ficoll-Hypaque gradient 
(21).  The interphase enriched in lymphocytes (>95%) was washed thrice with saline at 800 g  and 
the cell concentration adjusted to the desired level. The leukocytes that passed through the Ficoll- 
Hypaque gradient were predominately neutrophils (>90%).  These cells were then thrice washed 
with saline and used for absorption. The numbers or volumes of cells used for absorption are given 
in Tables III and IV. The cells were incubated with antiserum at room temperature for 30 min, 
centrifuged at 800 g  for cells, 4,000 g  for platelets, and the absorption repeated. 
Absorption  of  the  antisera  with  RNA  tumor  viruses  (partially  disrupted  by  freezing  and 
thawing)  or  gp71  and  p30  antigens  was  performed  as  follows:  Antiserum  (nine  volumes)  was 
incubated  overnight  at  4°C  with one  volume  of antigen  (protein concentrations of viruses  or 
antigens ranged from 0.1 to 1 mg/ml). The mixture was then centrifuged at 100,000g for 2 h and 
the supernate used for serological testing. 
Target Cells for Cytotoxicity Test.  The method of preparation of lymphoeytes or leukemic cell 
suspensions for cytotoxicity assays has been detailed earlier (14).  In short, the erythrocytes were 
sedimented with Plasmagel (HTI Corp.,  Associated Biomedic Systems,  Buffalo,  N.  Y.) and the 
supornate centrifuged at 800 g  for 10 rain.  The leukocytes suspended in plasma were added to a 
nylon column and incubated for 20 min at 37°C.  The cells were eluted from the column with warm 
Hanks' balanced salt solution (HBSS).  Tris buffer (0.17 M,  pH  7.2) was then added  to lyse the 
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types and immature cells of the granulocytic series were eluted from the nylon columns under 
these conditions. The cells were adjusted to a concentration of 4  ×  106/ml in HBSS for use in the 
microcytotoxicity  test. Unless specifically classified as cells from a remission patient, all leukemic 
test cells were from patients in relapse or the untreated stage of their disease. 
Cytotoxicity  and Cytotoxicity Inhibition Assays.  A two stage microcytotoxicity technique was 
used (14). 1 pl of antiserum (diluted in HBSS) was mixed with 0.5 pl of cells (4 × 106/ml) in Falcon 
microtest plates (no.  3034; Falcon Plastics, Div.  of BioQuest,  Oxnard,Calif.). The mixture was 
incubated for 35 min at room temperature, rabbit complement (C) (5 ~l) was added and the plates 
incubated at 37°C for another 35 min. Thereafter, 5 ~l of 5% eosin and 2/~l of 30% buffered  formalin 
were added and the cell death was assessed by phase-contrast microscopy. Cell lysis of 30%  or 
greater above normal serum controls was considered a positive reaction. When the number of cells 
lysed  in  the  C  controls was 30%  or  greater,  rabbit  C  absorbed with leukemic  cells (14) was 
substituted for the regular rabbit C in the cytotoxicity test. 
Competing antigenic activity in solubilized antigen and virus preparations was determined by 
inhibition of cytotoxic antisera to human leukemia-associated antigens or the antisera to oncorna- 
virus antigens. Serial dilutions of the antigen preparations (0.5  ~l) were incubated with 1 #al of 
antiserum for 1 h at 37°C. The dilution of antiserum used was determined on the day of testing by 
end-point titration of the particular antiserum with a  given target cell. The highest dilution of 
antiserum  giving  target  cell  lysis from  60  to  90%  was  used.  After  the  1-h  incubation  with 
antiserum,  0.5  #al  of target cells was added  and  the remainder of the test was performed as 
described for direct cytotoxicity. Competing antigen activity of a given preparation represented 
the amount of antigen required for a 50% reduction in the cytotoxic activity of the test antiserum. 
In each experiment, controls for the anticomplementarity of the antigen preparation were in- 
cluded. 
Results 
During the course of studies on the isolation and characterization  of human 
leukemia-associated membrane  antigens,  a  partially purified antigen fraction 
was obtained by DOC extraction of human leukemic cells which blocked not only 
the cytotoxic reactions of the primate antisera with human leukemic cell anti- 
gens, but also had activity by competition radioimmunoassay for the interspe- 
cies determinant of FLV gp71 (22). The nature of the competing activity will be 
reported in a  separate publication.  This finding,  however, prompted us to test 
various antisera  to FLV or FLV structural  components and  antisera  to other 
RNA tumor viruses for cytotoxic activity for normal and leukemic human cells. 
Cytotoxic Reactivity of Antisera to RNA Tumor Viruses and Viral Antigens 
with Human Cells.  The  antiserum  panel  described in Table I  was absorbed 
with HRBC and tested by microcytotoxicity with human normal and leukemic 
test cells. Of the antisera described in Table I only those to FLV and FLV gp71 
reacted with human  leukemic cells (Table II).  Antisera  to FeLV and primate 
RNA  tumor  viruses  not  listed  in  Table  I  were  also  studied.  The  cytotoxic 
reactivity of these antisera  with human  leukemic cells will be presented in a 
separate publication. The goat antiserum to FLV was cytotoxic for cells from all 
CGL, AML, and acute myelomonocytic leukemia (AMML) patients tested and 
reacted with cells from three of five ALL patients. The antiserum failed to react 
with  cells from  CLL patients,  normal  donors,  or AML  and  CGL patients  in 
clinical  remission.  The  remission patients  had no leukemic blast cells in the 
bone  marrow  or  peripheral  blood  by  morphological  criteria  and  both  bone 
marrow and peripheral  blood cells were nonreactive with the simian antisera 
detecting human leukemia-associated antigens. The goat and rabbit antisera to 
FLV gp71 were cytotoxic for cells from most or all CGL patients  and for cells METZGAR,  MOHANAKUMAR,  AND  BOLOGNESI  51 
TABLE  I 
Oncornavirus  Antiserum Panel Studied by Cytotoxicity 
Antiserum des-  Immunizing antigen  Species im-  Properties 
ignation  munized 
G-anti-RLV  RLV gp69/71 of RLV pro-  Goat  No  cross-reactivity  with  other 
gpTl*  duced  by JLSV5  mouse  RLV  structural  proteins  (34) 
cells 
Tween  ether  disrupted  Rabbit 
AMV 
R-anti-AMV 
R-anti-AMV  AMV gp85  Rabbit 
gp85 
R-anti-AMV  AMV p27  Rabbit 
p27 
R-anti-MMTV  gp52  (isolated  from  Rabbit 
gp52  mouse  mammary  tu- 
mor  virus  from  RIII 
milk) 
R-anti-STU  STU  tissue  culture  cells  Rabbit 
from  which  Eveline 
cells were derived 
Roanti-FCS  FCS  Rabbit 
G-anti-FLV  Tween  ether  degraded  Goat 
FLV from Eveline cells 
G-anti-FLV  gp71 of FLV from Eveline  Goat 
gp71  cells 
R-anti-FLV  gp71 of FLV from Evetine  Rabbit 
gp71  cells 
R-anti-FLV p30  p30 of FLV from Eveline  Rabbit 
cells 
R-anti-FLV  pl5(E) of FLV from Eve-  Rabbit 
pl5(E)$  line cells 
R-anti-FLV  p13 and pl5(E) from Eve-  Rabbit 
p13§  line cells 
R-anti-RLV  SDS-treated  RLV  from  Rabbit 
mouse plasma 
Reacts with  most of the  virion 
structural  components  (un- 
published) 
No  cross-reactivity  with  other 
AMV structural proteins (19) 
No  cross-reactivity  with  other 
AMV structural  proteins (18) 
No reactivity with C-type virus 
glycoproteins. Stains budding 
MMTV  by  immunoelectron 
microscopy  (unpublished) 
No reactivity with virus or puri- 
fied FLV antigens (22) 
Good precipitating antibodies to 
FCS (22) 
Virus specific.  Reacts preferen- 
tially with p30 and gp71. Se- 
rum  was  absorbed  with  nor- 
mal mouse antigens and FCS 
(36) 
No  cross-reactivity  with  other 
FLV  structural  components 
(22) 
No  cross-reactivity  with  other 
FLV  structural  components 
(22) 
No  cross-reactivity  with  other 
FLV  structural  components 
(16) 
No  cross-reactivity  with  other 
FLV  structural  components 
(35) 
Reacts with both p13 and pl5(E) 
(unpublished) 
Reacts  weakly  with  several 
MuLV structural components 
but strongly with p30(36) 
* Obtained from T. August, Albert Einstein College of Medicine, Bronx, N.  Y. 
$ pl5(E) is a distinct component present on the surface of the virus (37). 
§ p13 is a new antigen recently isolated from FLV. Its properties are currently being studied. 
from some patients with AMML. The antisera to FLV gp71  failed to react with 
cells from normal  donors  or patients  with AML,  CLL,  ALL, or with  CGL and 
AML patients in remission. The cytotoxic titers of the antisera to FLV and FLV 
gp71  ranged from  1:4 to  1:16 with target cell lysis from 50-100%  depending on 52  HUMAN  LEUKEMIA  AND  ONCORNAVIRUS  ANTIGENS 
TABLE II 
Cytotoxicity Testing of  Xenoantisera to RNA Tumor Virus Antigens with Human Cells 
Goat or rabbit antisera 
to RNA tumor virus  Normal 
antigens absorbed  donors 
with HRBC 
Cytotoxicity reactions with cells from 
leukemia patients 




Goat anti-FLV  0/12"  21/21  9/9  0/19  3/5  12/12  0/10 
Goat anti-FLV gp71  0/12  19/21  0/9  0/19  0/5  3/12  0/10 
Rabbit anti-FLV gp71  0/12  21/21  0/9  0/19  0/5  5/12  0/10 
Normal goat and rabbit  0/12  0/21  0/11  0/19  0/5  0/12  0/10 
serums 
* Number of donors whose cells gave >20%  increased lysis with antiserum over normal serum 
controls/number of donors tested. 
* Goat or rabbit antisera to these viruses, cells or antigens were also nonreactive with the above 
cells. FLV p30, FLV p15,  FLV p13,  RLV, RLV gp71,  MMTV gp52,  AMV, AMV gp85, AMV p27, 
STU cells, and FCS (see Table I). 
the donor tested. The other antisera described in Table I, including the antise- 
rum to STU cells from which the FLV-producing Eveline cells were derived, and 
the rabbit antisera to RLV gp71 or fetal calf serum (FCS), were nonreactive with 
human normal and leukemic cells by this technique. 
The  ability of the  antisera  to  FLV gp71  to  specifically lyse the  cells from 
human  CGL patients  suggested an  antigenic  relationship  between CGL cells 
and FLV gp71. Moreover, the cytotoxic reactivity of the antiserum to FLV with 
cells  from  patients  with  other  types  of leukemia  suggested  that  this  cross- 
reactivity might be via antibodies to FLV components other than  gp71.  Data 
from  radioimmunoassay  and  immunoprecipitation  studies  (22)  with  purified 
FLV antigenic  components  indicates  that  most of the  antibodies  in  the  FLV 
antiserum reacted with the p30 internal  virion component as well as with the 
gp71 surface glycoprotein.  In order to better define the specificity of the reac- 
tions of the FLV and FLV gp71 antisera with human leukemic cells, absorption 
studies were performed. 
Cytotoxic  Reactivity  of Absorbed FLV gp71  Antiserum  with Human  CGL 
Cells.  Portions of the rabbit antiserum to FLV gp71 absorbed with HRBC were 
additionally absorbed either with peripheral blood leukocytes, platelets, lympho- 
cytes, neutrophils,  or thymocytes from normal  donors,  or with leukemic cells 
from  individual  CLL,  AML,  or  CGL  patients.  In  addition,  samples  of the 
antiserum  were  also  absorbed with  various  oncornaviruses  or  their  purified 
antigenic components,  C57BL/6 spleen cells or STU embryo cells. The absorp- 
tions were performed as described in the Materials and Methods. The absorbed 
antiserum  was then tested by cytotoxicity with cells from CGL patients.  The 
results  are  summarized  in  Table  III.  Peripheral  blood  leukocytes,  purified 
platelets,  and  neutrophils  from five normal  donors  as well as cells from two 
different CGL patients were able to absorb out the cytotoxic activity of the gp71 
antiserum.  Human peripheral blood lymphocytes, thymocytes, and cells from at METZGAR,  MOHANAKUMAR,  AND  BOLOGNESI 
TABLE III 
Absorption  of Cytotoxic Activity of Rabbit Antiserum to FLV gp71 
53 
Antigens which absorbed out cytotoxic 
activity  of  anti-FLV gp71 antiserum 
when tested  with CGL cells 
Antigens which failed  to  absorb out  cytotoxic  activ- 
ity  of  anti-FLV gp71 antiserum when tested  with 
CGL cells 
Human blood neutrophils (2 × 108/ml)  * 
Human blood platelets (equal volume 
packed cells) 
CGL cells (2 x 108/ml) 
FLV (0.25 mg/ml) 
FLV gp71 (0.06 mg/ml) 
FLV spleen cells (2 × 108/ml) 
FLV (animal passaged) (0.1 mg/ml) 
HRBC  (3 volumes packed cells/l  volume antise- 
rum)$ 
Blood lymphocytes (3 × 108/ml) 
Thymocytes  (3 × 108/ml) 
AML cells (3 × 108/ml) 
CLL cells (3 × 108/ml) 
FLY p30 (0.6 mg/ml) 
MMTV gp52 (1.0 mg/ml) 
AMV gp85 (0.5 mg/ml) 
AMV (1.0 mg/ml) 
GLV (0.9 mg/ml) 
RLV (1.0 mg/ml) 
STU cells (1 volume  packed cell homogenate/volume 
antiserum (22) 
C57BL/6 spleen cells (3 × 108/ml) 
* Number in  parentheses in  this  column represents  the number of  cells  or  protein  concentration  of 
virus or virus antigens which completely blocked the cytotoxic  activity  of the FLV  gp71 
antiserum with CGL cells.  This does not necessarily  represent the minimum cell  number or 
protein  concentration which will  inhibit. 
Number in parentheses in this  column represents the maximum  number of cells  or protein 
concentration of virus or virus antigens which failed  to give 50% reduction in the cytotoxic 
activity  of  the FLV gp71 antiserum with CGL cells. 
least two different CLL and AML patients did not affect the cytotoxic antibody 
titer of the serum with target cells from CGL donors. Absorptions have not as 
yet been done with cells from AMML patients. This suggests that platelets and 
neutrophils from normal individuals do express an antigenic determinant which 
cross-reacts with one of the determinants detected by the rabbit antiserum to 
FLV gp71  (see Discussion).  Mouse passaged FLV and spleen cells from FLV- 
infected mice as well as the FLV and FLV gp71 antigens were able to absorb out 
the cytotoxic reactivity of the antiserum to FLV gp71  when tested with CGL 
target cells. In contrast, FLV p30, RLV, GLV, AMV, AMV gp85, and MMTV 
gp52,  as well as embryo cells from STU and C57BL/6 mice did not affect the 
cytotoxic reactivity of the gp71 antiserum.  Quantitative data on the ability of 
FLV and FLV gp71 antigen preparations to inhibit the cytotoxic reactivity of  the 
FLV gp71  antiserum with cells from a  CGL patient are shown in Fig.  1. The 
FLV gp71 antigen gave complete inhibition at a concentration of 0.06 mg/ml and 
50%  inhibition at  a  concentration of 0.03  mg/ml.  The FLV  preparation also 
inhibited this antibody target cell combination, but less effectively than gp71, 
which is consistent with the proportion of gp71 (about 5-10% of total protein) in 
the virus particle (23). AMV at 1 mg/ml or FLV p30 at 0.6 mg/ml (not plotted in 
Fig.  1) failed to inhibit the reactivity of the gp71 antiserum with CGL cells. A 
specificity control for these inhibitions can be seen in Table V where FLV and 54  HUMAN  LEUKEMIA  AND  ONCORNAVIRUS  ANTIGENS 
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FIG.  1.  Inhibition of cytotoxic reactivity of FLV gp71 antiserum with CGL cells. FLV and 
FLV gp71  inhibited the reaction, whereas AMV did not. FLV p30 at a concentration of 0.6 
mg/ml (not plotted) also failed to compete for cytotoxic activity with this antiserum-target 
cell combination. 
FLV gp71 fail to inhibit the reactivity of a chimpanzee antiserum to CLL cells. 
These antigens were also not inhibitory to the specific cytotoxic activity of HL-A 
antisera with peripheral  blood lymphocytes of normal donors. 
Cytotoxic  Reactivity  of Absorbed  FLV  Antiserm  with  Human  Leukemia 
Cells.  The goat antiserum  to FLV was similarly absorbed with HRBC, blood 
neutrophils,  and  platelets  from  normal  donors  and  with  leukemic cells from 
CLL, CGL, and AML donors. When absorptions were done with human cells at 
least  two  different  absorbing  cell  donors  were  used  in  each  category.  The 
antiserum was also absorbed with FLV gp71 and p30 antigens from FeLV and 
FLV.  In some instances,  the  antiserum  after absorption with  either  AML or 
CGL cells was additionally absorbed with FLV gp71, FLV p30, or platelets. The 
samples of absorbed antiserum were then tested with cells from CGL, AML, or 
AMML patients (Table IV). The number of patients in each category that were 
studied varied with each portion of absorbed antiserum.  Absorption of the FLV 
antiserum with CGL cells removed the reactivity for cells from at least 12 other 
CGL patients  tested but left cytotoxic reactivity for cells from  7 AML and  5 
AMML  patients.  Cells  from  the  2  AML  patients  used  to  absorb  the  FLV 
antiserum  removed reactivity for cells from the 7 AML and 5 AMML patients 
but left activity for cells from the 10 CGL patients tested. Absorption of the FLV 
antiserum with blood neutrophils and platelets from normal donors or with FLV 
gp71 gave the same results as absorption with CGL cells, i.e., reactivity was lost 
for cells from all CGL donors but was retained for cells from AML and AMML 
patients. Furthermore,  absorption of the FLV antiserum with FLV p30 or FeLV 
p30 did not affect the reactivity for CGL cells but did remove all reactivity for 
cells  from  the  AML  or  AMML  patients.  When  the  antiserum  to  FLV  was 
absorbed with cells from CGL donors plus FLV p30 or when absorption was done 
with AML cells plus FLV gp71 or human platelets, all cytotoxic reactivity was 
lost. 
The data from Tables III and IV suggest that the antiserum to FLV gp71 is 
reacting  with  a  FLV gp71-1ike determinant  on CGL cells  and  on some other 
myeloid cells including platelets of normal individuals.  This antigenic determi- 
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TABLE  IV 
Results of Absorption of Goat Antiserum to FLV 
FLV antiserum 
absorbed with: 
Number of cells or 
protein concentration 
of antigen used for 
absorption 
Cytotoxicity reactions with 
cells from leukemic patients 
CGL  AML  AMML 




CGL  2  ×  10S/ml  -$  +  + 
AML  2  ×  108/ml  +  -  - 
CLL  3  ×  108/ml  +  +  + 
Platelets  Equal volume  -  +  + 
packed cells 
Blood neutrophils  3  x  10a/ml  -  +  + 
FLV gp71  1.0 mg/ml  -  +  + 
FLV p30  0.6 mg/ml  +  -  - 
FeLV p30  1.0 mg/ml  +  -  - 
CGL +  FLV gp71  1.0 mg/ml  -  +  + 
CGL +  FLV p30  1.0 mg/ml  -  -  - 
AML  +  gp71  1.0 mg/ml  -  -  - 
AML  +  platelets  1.0 mg/ml  -  -  - 
*  +,  positive cytotoxic reaction.  >50% increased lysis of FLV goat antiserum above normal goat 
serum  controls.  Cells from  at  least three donors with this degree of positive reactivity were 
tested in each patient category. 
-,  negative cytotoxic reaction.  < 10% increased lysis of FLV goat antiserum above normal goat 
serum controls. Cells from at least five donors were tested in each patient category. 
lymphoid cells from normal donors. The antiserum to FLV appears to also detect 
this gp71-1ike antigen on CGL cells and in addition, detects another antigen 
which cross-reacts with FLV p30 and FeLV p30 on cells from AML, AMML, and 
certain ALL donors. The p30-1ike antigen on AML and AMML cells detected by 
the FLV antiserum has not been detected on normal peripheral blood cells. 
Inhibition  and Absorption  with Oncornavirus Antigens of Nonhuman Pri- 
mate Antisera to Human Leukemia-Associated Antigens.  In order to further 
establish  the  relationship  between FLV  antigens  and human leukemic cell 
membrane antigens, various tumor viruses and their antigens were tested for 
their ability to  inhibit  the  cytotoxic reactions of simian  antisera to  human 
leukemia-associated antigens. The ability of these antisera to define antigens 
specific for human myeloid or lymphocytic leukemia cells has been referenced 
and summarized in the introduction to this paper. The technique for performing 
the  cytotoxic inhibition  is  described in  the  Materials  and  Methods  and  its 
applicability for detection of subcellular and soluble human leukemia-associated 
antigens has been previously described (24). Serial dilutions of FLV gp71 and 
the virus suspensions of FLV, FeLV, AMV, and MMTV (partially disrupted by 
freezing and  thawing)  were tested for their capacity to  block  the  cytotoxic 
reactivity of four different simian antisera with human leukemic target cells. In 
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TABLE V 
Inhibition of Cytotoxic Activity of  Simian Antisera to Human Leukemia-Associated Antigens 
Cytotoxic inhibition  with  antigens  from: 
Antiserum-target 
cell combination  CGL  CLL  FLV  FLV  FeLV  AMV  MMTV  extract  extract  gp71 
Monkey  anti-CGL  +*  (0.12)  -$  (4.0)  +  (0.25)  +  (0.06)  -  (1.0)  -  (1.0)  -  (1.0) 
(M3)  +  CGL  cells 
Chimpanzee  anti-  +  (0.12)  -  (4.0)  +  (0.25)  +  (0.06)  -  (1.0)  -  (1.0)  -  (1.0) 
AML  (C2)  +  CGL 
Chimpanzee  anti-  +  or  -  -  (4.0)  +  or  -  -  (1.20)  -  (1.0)  -  (1.0)  -  (1.0) 
AML  (C2)  +  AML  (0.12)  (0.25) 
cells 
Chimpanzee  anti-CLL  -  (1.00)  +  (0.2)  -  (1.00)  -  (1.20)  -  (1.0)  -  (1.0)  -  (1.0) 
(C1)  +  CLL  cells 
*  +, significant  inhibition.  50% or greater  reduction  of antibody-target  cell lysis. Number  in parentheses 
represents  minimum  antigen  concentration  (mg/ml)  giving  50% or greater  reduction. 
-,  no  inhibition.  Less  than  50%  reduction  of  antibody-target  cell  lysis.  Number  in  parentheses 
represents  maximum  antigen  concentration  (mg/ml) tested. 
partially purified on a  Sephadex G200 column and also included in the study. 
The  result  of competition  of these  antigens  with  various  simian  antiserum 
target  cell  combinations  is  given  in  Table  V.  It  should  be  emphasized  that 
antisera C2 (chimpanzee anti-AML) and M3 (monkey anti-CGL) are not mono- 
specific (14) and that antigens such as the CGL extract,  FLV,  FLV gp71,  and 
FLV p30 could give different inhibition  results when these antisera  are tested 
with cells from other AML or CGL patients. Absorption studies with cells from 
individual AML and CGL donors have already demonstrated the oligospecificity 
of the  myeloid leukemia  antigens  detected by these antisera  (14).  FLV,  FLV 
gp71,  and the detergent-extracted  antigens  of cells from one CGL donor gave 
50% or greater inhibition (at concentrations ranging from 0.06 to 0.25 mg/ml) of 
the reactions of the simian antisera (M3 and C2) with cells from a CGL patient. 
However, when antiserum  C2 was tested with cells from an AML donor, FLV 
gp71  failed to  inhibit  the  reaction  of this  antiserum-target  cell  combination, 
whereas the FLV preparation was inhibitory. The FLV and FLV gp71 antigens 
failed to inhibit the cytotoxic reactivity of the C1 antiserum (anti-CLL) to cells 
from  CLL  patients.  The  C1  antiserum-CLL  target  cell  combination  was  in- 
hibited only by the detergent extract of CLL cells. None of the other oncornavi- 
ruses tested (FeLV, AMV, and MMTV) at the concentrations noted gave signifi- 
cant inhibition of the four simian antiserum-target cell combinations. This data 
provided preliminary evidence that some of the reactions of the simian antisera 
to  myeloid leukemia  antigens  might  be specifically blocked by FLV or FLV 
gp71.  However,  the  inhibition  of a  C-dependent  serological  reaction  of an 
oligospecific antiserum  could be misleading  due to a  possible anticomplemen- 
tary  effect of antigen-antibody  complexes.  Therefore,  absorption  followed by 
ultracentrifugation  (in order to remove the complexes from the antiserum) was 
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TABLE  VI 
Absorption  of Chimpanzee Antiserum to AML Cells with FLV and FLV gp71 
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Dilution of  Cytotoxicity reactions with cells from individual leukemia patients 
chimpanzee  CGL-  CGL- 
antiserum  AML  AML  AML  AML 
CGL 1  CGL 2  blast  blast 
(C2)  1  2  3  4 















70*  70  90  80  90  100  70  90 
60  60  90  80  90  100  60  90 
60  50  80  90  90  100  60  90 
--$  --  90  80  90  100  60  90 
--  --  80  70  90  100  70  80 
--  --  80  70  90  100  40  80 
50  50  70  60 
50  40  60  40 
50  --  40  30 
* Number represents % dead cells when antisera gave >30% increased lysis above normal serum 
controls. 
Represents less than 30% increased lysis above normal serum controls. 
Undiluted C2 antiserum was absorbed with FLV and FLV gp71 as described 
in the  Materials  and  Methods.  The unabsorbed and  absorbed antiserum  was 
then tested with cells from various CGL and AML patients at dilutions from 1:2 
to  1:8.  Different  results  depending  on  the  individual  cell  tested  were  noted 
(Table  VI).  Absorption  with  FLV  gp71  completely removed the  reactivity  of 
antiserum  C2 for cells from two different CGL donors and corresponded well 
with the inhibition  data in Table V. The FLV gp71 antigen,  however, did not 
alter the reactivity of this antiserum with cells from four different AML patients 
and the two CGL patients  in blast crisis.  Cells from the two CGL patients  in 
blast crisis show a reactivity similar to cells from certain AML donors, instead of 
reacting like cells from CGL patients not in blast crisis.  Absorption with FLV 
removed the reactivity of the  antiserum  for cells from the two CGL patients 
which  were  also  affected by absorption  with  FLV  gp71.  However,  FLV also 
removed  the  cytotoxic reactivity for cells  from  two AML  patients  that  were 
unaffected  by FLV  gp71  absorption.  Subsequent  to  absorption  with  FLV,  a 
decrease in percent lysis and titer was noted for cells from the two CGL patients 
in blast crisis and the other two AML patients.  This type of absorption pattern 
was also noted in previous studies when another AML antiserum was absorbed 
with cells from individual CGL donors and then tested with cells from CGL and 
AML donors (text Fig. 1 in reference 14). Absorption of antiserum C2 with FLV 
p30 and other internal antigens is in progress in order to determine whether the 
effect of FLV absorption  and testing with AML donors three  and four can be 
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Thus  it  appears  that  FLV  and  FLV  gp71  possess  some  of the  antigenic 
determinants that are being detected by the simian antisera to human myeloid 
leukemia  antigens.  However,  since  the  simian  antisera  have  already  been 
absorbed with human neutrophils and platelets, it seems likely that the determi- 
nant on the FLV gp71 molecule reacting in this  system is different from that 
being detected on normal human myeloid cells by the rabbit antiserum to FLV 
gp71 (see Discussion). 
Discussion 
This report demonstrates a unique antigenic similarity between certain FLV 
antigens and membrane-associated antigens on some human myeloid leukemia 
cells. The serological relationships, however, are complex, which in part may be 
a  reflection  of the  various  types of antigens  studied  and  the  immunological 
perspective of the different species of animals used for antibody production. 
The antigenic determinants detected by the cytotoxicity reactions of the FLV 
gp71 antiserum with human CGL appears to be different from the determinant 
on FLV gp71 responsible for the inhibition of simian antisera to human myeloid 
leukemia antigens. The cytotoxic reactivity of the rabbit antiserum to FLV gp71 
can be completely absorbed by peripheral  blood neutrophils  or platelets from 
normal donors. This reactivity is, therefore, not leukemia specific and probably 
represents a cross-reaction with a determinant on the FLV gp71 molecule which 
is also expressed on some normal human myeloid cells. The FLV gp71 determi- 
nant being detected in the cytotoxicity assay with human CGL cells is probably 
different from the usual group-specific or interspecies-specific determinant de- 
fined by the FLV gp71 antiserum by radioimmunoassays, immunodiffusion, and 
C fixation, since an antiserum to the RLV gp71 antigen which shares group- and 
interspecies-specific determinants with FLV (25) fails to react with human cells. 
However, Fink  et al.  (26) have reported  a  cross-reactivity by immunofluores- 
cence between an antiserum to RLV and bone marrow cells from patients with 
erythroleukemia,  other blood dyserasias, and nonleukemic malignancies.  RLV 
and  GLV  also  fail  to  absorb  the  cytotoxic  reactivity  of the  anti-FLV  gpT1 
antiserum for human CGL cells, suggesting that the cross-reacting determinant 
detected by this antiserum  does not relate to the group or interspecies moiety 
but may be associated with the type-specific portion of the molecule. However, 
another possible explanation for these results is that virus preparations such as 
the RLV and GLV used in this study may have lost a significant portion of their 
gp71 during purification.  This phenomenon has been shown to occur in FLV by 
Moennig et al. (17). More detailed studies with appropriately absorbed antisera 
to FLV gp71 will be necessary to determine the molecular nature of the human 
CGL-FLV gp71 cross-reactivity. 
The inhibition by FLV gp71 of the cytotoxicity reaction of the simian antisera 
to human myeloid leukemia-associated antigens, however, appears to be related 
to  the  leukemic  process.  The  primate  antisera  to  human  myeloid  leukemia 
antigens  have  already  been  absorbed with  peripheral  blood neutrophils  and 
platelets from normal donors.  The number of cells used for this absorption,  as 
noted  in  other  studies,  is  adequate  for the  removal  of antibodies  reactive to 
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the inhibition of the simian antisera by FLV gp71 is related to specific antigens 
present on myeloid leukemic cell membranes. 
The cytotoxic activity of the FLV antiserum with human CGL cells is proba- 
bly due to antibodies to FLV gp71. This reactivity is lost by absorption with FLV 
gp71, normal human platelets or cells from CGL donors. Failure of AML cells to 
absorb out this reactivity indicates the antigen is not present on these cells. In 
contrast,  the  cytotoxic activity of the  FLV antiserum  with AML cells  is not 
affected by absorption  with  FLV gp71,  human  peripheral  blood neutrophils, 
platelets,  or CGL cells but is removed by absorption with p30 antigens  (Table 
IV). Since both FLV p30 and FeLV p30 absorb the cytotoxic activity of the FLV 
antiserum for AML cells, it may well be that the cross-reactivity between FLV 
p30 and  AML cells  is due to the  interspecies-specific  determinant.  However, 
direct cytotoxic testing on AML cells with rabbit antisera to p30 did not reveal 
the expected activity. When tested on FLV-producing murine Eveline cells, the 
FLV p30 antiserum  is cytotoxic, but the end-point titer  is considerably lower 
than  that  obtained  with  gp71  antiserum  (27).  The  failure  of the  FLV  p30 
antiserum  to lyse human cells may reflect the quantitative  or spatial distribu- 
tion of the antigen on the membrane of these cells. It is also possible that the p30 
preparation used to elicit the antisera were somehow modified during purifica- 
tion such that antibodies were not produced against the cross-reactive determi- 
nant. 
The nature of the molecular species on the human leukemic cell surface which 
cross-reacts with FLV gp71 and p30 is presently under investigation.  Attempts 
to specifically immunoprecipitate  similar  molecules from antigen-positive  hu- 
man leukemic cells with antisera to FLV gp71 have resulted in multiple molecu- 
lar species in the immunoprecipitates  of which one is a  glycoprotein of about 
55,000 daltons mol wt. Although this molecular species is not detectable in anti- 
gen-negative cells, its relationship to the viral gp71 remains to be established. We 
have been able to determine,  however, that enzymatic removal of a  significant 
portion of the carbohydrate on gp71 (28) does not eliminate its cross-reactivity 
with human CGL antigens, thereby minimizing the possibility that we are deal- 
ing with a  spurious cross-reactivity similar to the Forssman antigen. 
We do not feel that the data presented in this report are sufficient to conclude 
that human CGL or AML are caused by an RNA oncogenic virus.  However, it 
does imply that whatever the mechanism of leukemogenesis in man may be, it is 
associated with the expression of at least two membrane antigens  on myeloid 
leukemia cells which cross-react with well characterized components (gp71 and 
and p30) of FLV. There are certain studies which indicate a possible viral associa- 
tion with human leukemia. Gallagher and Gallo (29) reported an isolate from an 
AML  patient  with  characteristics  of primate  C-type  viruses,  and  Sherr  and 
Todaro (4) found that cells from some AML patients contain material which cross- 
reacts with p30 of primate oncornaviruses.  The cross-reactivity of p30 and gp71 
molecules between murine  and certain primate RNA viruses (simian sarcoma 
and gibbon ape lymphoma) has already been established (25, 30, 31). Moreover, 
another example of how an endogenous virus gene product of one species may 
show cross-reactivity with an antigen of oncornaviruses closely associated with a 
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(32). These investigators isolated an endogenous C-type particle from an Asian 
mouse Mus-caroli which shows strong p30 and reverse transcriptase cross-reac- 
tivity with type C viruses from the woolly monkey and gibbon ape. This study 
may also relate to our finding of a  cross-reactive gp71 determinant on certain 
malignant and normal human myeloid cells which is also present on a molecule 
(FLV gp71) associated with leukemogenesis in the mouse. 
In addition, preliminary studies in our laboratory similar to those described in 
this  report  suggest that  there  is  another  independent relationship  between 
antigens of primate RNA tumor viruses and membrane-associated antigens of 
CLL, ALL, and AML cells.  Our  approach has been to test the ability of the 
primate  oncornaviruses and  their  antigens to  inhibit  or  block  the  cytotoxic 
activity  of rabbit  and  simian  antisera  that  are  defining human  leukemia- 
associated antigens different from those studied in this report.  In animal sys- 
tems,  it is known that different leukemogenic RNA  viruses have strain and 
species specificity, as well as the capacity to induce different forms of leukemia. 
The  species  of the  host  cell  infected or  transformed by  the  virus  may also 
influence the cross-reactive antigenicity. For example, Mann et al. (33) studied 
the cytotoxic reactivity of a rabbit antiserum to a papain digest preparation from 
the  RAJI  lymphoblastoid  cell  line  (originally  derived  from  a  patient  with 
Burkitt's lymphoma). This antiserum detected a  leukemia-associated antigen 
on human embryonic kidney lines after infection with RLV, Kirsten, or SV-40 
virus.  However,  mouse cell lines infected with RLV and Kirsten virus  were 
nonreactive. 
The goat and rabbit antisera to FLV and FLV gp71 are already proving to be 
valuable diagnostic and prognostic reagents for the detection of human leuke- 
mia-associated antigens in clinical studies at Duke University, Durham, N. C. 
Our rabbit and nonhuman primate antisera to AML and CGL leukemia anti- 
gens  do  not  easily  distinguish  these  two  types  of leukemia.  However,  the 
cytotoxic reactions of the rabbit antiserum to FLV gp71 and the goat antiserum 
to FLV, provides a  serological means for making this distinction.  One  of the 
major obstacles in the large scale production and distribution of xenoantisera to 
human leukemia-associated antigens for diagnosis or therapy is that most of the 
current antisera to human leukemia cells require exhaustive and tedious absorp- 
tions with normal human tissue cells before they are rendered leukemia spe- 
cific. If the antigenic relationship of RNA tumor viruses with human leukemia 
antigens can be well established and if  different specificities based on morpholog- 
ical  types of human leukemias  are  noted,  it  may be  that  immunization of 
animals with the  appropriate  purified viral  protein  will result in leukemia- 
specific antisera that do not require large scale absorptions with normal human 
tissue cells. 
Summary 
Leukemic cells  from  all  human chronic  granulocytic leukemia (CGL)  and 
some  acute  myelomonocytic leukemia  (AMML)  donors  are  lysed  by  rabbit 
antisera to a purified glycoprotein of Friend murine leukemia virus (FLV gp71) 
in  a  microcytotoxicity assay.  These  antisera  are  not  cytotoxic to  cells  from 
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(ALL), chronic lymphocytic leukemia (CLL), or to peripheral blood lymphocytes 
from normal donors. A goat antiserum to gradient purified FLV in addition to 
reacting with cells from CGL and AMML donors also reacted with cells from 
AML patients and some ALL donors.  However, this antiserum failed to react 
with cells  from CLL patients.  Peripheral blood and  bone marrow leukocytes 
prepared  from  leukemic  patients  in  clinical  remission  failed  to  react  with 
antisera to FLV and FLV gp71.  Absorption experiments demonstrated that the 
antigen on CGL cells which is reacting with the antiserum to FLV gp71 is also 
present on normal human platelets and neutrophils. Similar absorption studies 
showed that the antigen on AML cells detected by the FLV antiserum is not 
present on normal  leukocytes and platelets and  appears to be  related to the 
major internal p30 antigens of mammalian RNA tumor viruses. 
Another antigenic relationship between oncornaviruses and membrane anti- 
gens  of human leukemia cells  was  shown  by the  ability of FLV antigens  to 
absorb the cytotoxic reactivity of nonhuman primate antisera detecting human 
leukemia-associated antigens. FLV and FLV gp71 antigens were able to absorb 
all  cytotoxic activity of monkey and  chimpanzee antisera  to human  myeloid 
leukemia antigens when these antisera were tested with CGL cells. 
These  two  approaches  to  an  analysis  of cross-reactivity indicate  that  the 
antigenic determinant(s) detected by the cytotoxic reactions of the  FLV gp71 
antiserum with human CGL cells is different from the determinant on FLV gp71 
which is responsible for the inhibition of the reactivity of simian antisera with 
CGL cells. 
Since the goat and rabbit antisera to FLV and FLV gp71  are able to distin- 
guish AML from CGL cells by direct cytotoxicity testing and absorption, they 
may be valuable reagents for the serological diagnosis of myeloid leukemia. In 
addition, since peripheral blood cells from AML and CGL patients in clinical 
remission  were  seronegative,  the  antisera  may  be  valuable  as  management 
aids. 
The data in this report indicates that whatever the mechanism of leukemogen- 
esis  is  in man,  cells from CGL and AML patients possess certain membrane 
antigens  which cross-react with FLV structural components such  as p30  and 
gp71. 
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